Statins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer

Basit Öğe Kaydı
dc.contributor.authorSahin, T.
dc.contributor.authorOrhan, C.
dc.contributor.authorOzercan, I
dc.contributor.authorMuglu, H.
dc.contributor.authorEr, B.
dc.contributor.authorAkyildiz, A.
dc.contributor.authorGuven, D.
dc.date.accessioned2026-08-12T18:13:27Z
dc.date.issued2026
dc.departmentFırat Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.issn1078-0432
dc.identifier.issn1557-3265
dc.identifier.urihttps://hdl.handle.net/11508/64414
dc.identifier.volume32
dc.identifier.wosWOS:001724426403015
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherAmer Assoc Cancer Research
dc.relation.ispartofClinical Cancer Research
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.titleStatins enhance trastuzumab deruxtecan efficacy: Preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu